Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mindfulness may ease anxiety for seniors with memory worries

NCT ID NCT03005652

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an 8-week mindfulness program could reduce anxiety in 168 older adults who have memory concerns but normal cognitive test scores. Participants were randomly assigned to either mindfulness training or a health education program. The goal was to see if mindfulness could improve mental health and potentially slow future cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mindfulness training
What this could lead to
If it works, this could offer a drug-free way to ease anxiety in people worried about their memory, potentially slowing cognitive decline.
What could go wrong
This is a completed study with 168 participants, so results are limited. The benefit may be small or not last long, and mindfulness requires time and effort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

168 people

The number who actually took part.

Started

Apr 2017

Finished

Sep 2018

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 60 years * Meet the research criteria proposed by the international SCD-I working group for studies in SCD * Performance within the normal range on standardised cognitive tests according to agreed study-specific standards to rule out mild cognitive impairment (MCI) and dementia * Either referred to the memory clinic by a physician or who are self-referrals because of memory concerns (assessed by a positive response to the question 'Are you worried about your memory?') * Ability to provide informed consent in accordance with International Conference on Harmonization of Good Clinical Practice (GCP/ICH) guidelines and local regulations * State that they are available for the trial duration Exclusion Criteria: * Presence of a major neurological or psychiatric disorder (including generalised anxiety, major depressive disorder, or an addiction to alcohol or drugs) according to ICD-10 and/or DSM 5 criteria * Under legal guardianship or incapacitation * History of cerebral disease (vascular, degenerative, physical malformation, tumor, or head trauma with loss of consciousness for more than an hour) which interferes with the aims of the study protocol * Presence of a chronic disease or acute unstable illness (respiratory, cardiovascular, digestive, renal, metabolic, hematologic, endocrine or infectious) which interferes with the aims of the study protocol * Current or recent medication that may interfere with cognitive action (psychotropic, systemic corticosteroid, anti-Parkinson's, or analgesic drugs). The interfering nature of the different treatments will be at the discretion of the investigating doctor. * Have regularly or intensively practiced meditation or comparable practices (yoga, Qi Gong, Alexander technique) * more than one day per week for more than six months consecutively over the last 10 years, * intensively (internship or retreat \> five consecutive days) over the past 10 years, * more than 25 days of retreats (cumulatively) prior to the last 10 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction Health Education Psychological Well-Being subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Clinical Research Memory Centre of Lyon (CMRR), department of the University Hospitals of Lyon - Hospices Civils de Lyon (HCL)

    Lyon, France

  • The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)

    Barcelona, Spain

  • The Department of Psychiatry at University of Cologne (UKK)

    Cologne, Germany

  • The Division of Psychiatry at University College London (UCL).

    London, England, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.